Exchange: NASDAQ·Updated 07:59 PM EST
IONS logo

IONS Ionis Pharmaceuticals Inc

$26.58
$0.64
(2.35%)
Today
Closed $26.58
$0.18
(0.68%)
After Hours
Reported EarningsNov 9
Mkt Cap$4.43B
Vol3.19M

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
45

Neutral Sentiment

How do you feel about IONS?

chartistmind
$IONS do you see my conviction? I am almost at breakeven now. But but how? Charts, system, conviction $TTD
7
murphylaw
$IONS not expected but good opportunity to load up or average down. Steal at this price.
5
FlipTop1979
$IONS Starting to lose patience. I swear they could come up with the cure for old age, and the stock would drop $5.
5
murphylaw
$IONS Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $70 From $85, Maintains Outperform Rating. Hopefully next week will be epic after EU Approval
4
OilBoomer
$IONS essentially at its 5 year low, this is gonna swing 50% one way or another the next 12 months. Got in at 29 but will make one more buy if it hits 25. After that, just gonna let the cards play out how they will.
3
LowBallerz
$IONS I’m certainly no expert but I firmly believe IONS has gone under the radar for a while due to some underwhelming headlines. They have some extremely positive revenue sources already in place which could bring the share price back to life. I wouldn’t be at all surprised with revenue potentially touching £200m this quarter and a 25% increase forecast for next. Based on the current share price trajectory, I can honestly see IONS opening at least 8-15% higher based on how undervalued it has been YTD. This is of course based more on a report that focusses on forward guidance. I also don’t think a hit/miss for EPS will matter all that much.
3
skeezbag
$IONS at least the CEO got close to the high. Shareholders were warned regarding the breadth of insider sales and consistently lying CEO Good luck doesn't mean I wish you losses
2
Equireason
$IONS Tryngolza 2026 sales guidance is now about USD 50M, down from USD 100-110M. With USD 41M sold through September and USD 9M of that in Q3, the new figure points to a Q4 near Q3's level rather than a ramp. Dawnzera carried the quarter at USD 37M, and the USD 875-900M total revenue guide was kept.
2
roosterly9
$IONS great drug, not very bright CEO, tribble sales effort. They sould be at 80% payor coverage. If there is only 30% payor coverage and paitients complain that doctor's prescription can not be filled because insurance do not pay, doctors will stop prescribing. If you have secured only 30% payor coverage that is not something to brag about, put the horse in front of the cart, get the insurance to pay for it before pushing the doctors. This company has serious management problem. I am long and hoping that despite the useless bunch of executive thai and and that, they will eventually figure ouit how to sell. Hire smart people.
2
onefryshy
$IONS Bollinger bands are as tight as they've ever been. I expect the resolution from this price range within probably 2 or 3 days...
2
PantySniffer69420
$IONS This just want to pop a hard on in your face. First stop 62.34. Then another at 83.92.
2
onefryshy
$IONS The sell-off this morning on very light volume... As a side note, ionis was ranked number one by Science as best employer in the industry, it was number two last year.
2
Chargedone
$IONS Ionis Pharmaceuticals (NASDAQ: IONS) and its partners have three primary candidates positioned for FDA New Drug Application (NDA) submissions across late 2026 and 2027, led by ulefnersen, sefaxersen, and obudanersen (ION582).
1
Chargedone
$IONS 7 FDA-approved medicines Wholly Owned Approved Medicines (Marketed by Ionis) • ZANVASTRO™ (zilganersen): first and only disease-modifying treatment for Alexander disease • DAWNZERA® (donidalorsen): prophylactic treatment to prevent hereditary angioedema (HAE) • TRYNGOLZA® (olezarsen): reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), reduce triglycerides and acute pancreatitis risk in adults with severe hypertriglyceridemia (sHTG). Partnered Approved Med • HIBSAGO™ (bepirovirsen): Marketed by GSK for the treatment of chronic hepatitis B. • WAINUA™ (eplontersen): Marketed by AstraZeneca for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). • QALSODY® (tofersen): Marketed by Biogen under accelerated approval for amyotrophic lateral sclerosis (ALS) linked to a mutation in the SOD1 gene. • SPINRAZA® (nusinersen): Marketed by Biogen as the first approved treatment for spinal muscular atrophy (SMA) in pediatric and adult patients.
1
murphylaw
$IONS RBC Cuts Price Target on Ionis Pharmaceuticals to $60 From $85, Keeps Outperform Rating. This is a steal. Grab some.
1
shoc24
$IONS reported earnings before the open today. GAAP EPS beat estimates: -$0.66 vs. -$1.23 expected, according to Stock Meadow.
1
Masonic__Being
$IONS ON 5 YR CHART SUPPORTS 🤯 ‼️= 31 +30 +⚠️👇 27 <-- ROCK BOTTOM hasn't gone below it in the 5-year chart at least clear by if it gets that low but you can never tell
1
Masonic__Being
$IONS DAMMMMM a fall from grace Added to my drop list I'll research later I just saw a goodbye on a ticker
1
Airbags
$IONS anyone think this is going to drop after today? Almost feels like all the PTs are going to be adjusted over next few days causing more drops. Anything that could be a catalyst to keep this stable?
1
Airbags
$IONS I was not expecting this. Is this an over reaction? His stock looked solid to me. Looked like a lot of good money behind it.
1

Advertisement|Remove ads.